Moderna stock resistance test at $197.74: Key levels to watch

Traders Union
All News
Stocks
Moderna rises 0.21% to $187.91 today

Highlights

Moderna received FDA approval for its mRNA flu vaccine with phase 3 data showing higher efficacy than standard options.
The company added Juan Andres as Chief Operating Officer and joined the Nasdaq-100, expanding its management and index presence.
Shares of Moderna trade below short- and medium-term averages, likely to fluctuate from $175.22 to $200.60 with a prevailing downside bias.

FDA flu vaccine approval and executive hire lift commercial outlook

Moderna received FDA approval for its mRNA-based flu vaccine, following phase 3 trials that demonstrated improved efficacy compared with standard flu vaccines, as reported by Ajmc. This regulatory milestone broadens Moderna's commercial portfolio and supports near-term revenue prospects. The company also appointed Juan Andres as Chief Operating Officer in a newly created role, which may enhance its operational capacity, according to Finance Yahoo. Additional developments include joining the Nasdaq-100 index and upcoming data presentations on individualized cancer therapies, while options trading volumes have also seen record highs, reflecting increased market activity.

Mixed momentum and prevailing seller bias cap near-term upside

Technically, MRNA is trading beneath both the MA-20 and MA-50, indicating sustained short-term and medium-term resistance. The Ichimoku Kijun on the daily timeframe is set at $197.74, marking the immediate resistance level, while volatility remains elevated. Momentum indicators show mixed signals: MACD and ADX are neutral, while both RSI and CCI point to a sell bias. Stochastic RSI highlights oversold conditions and Bull/Bear Power confirms persistent seller dominance. The Awesome Oscillator further supports the ongoing downtrend, underscoring the divergence between neutral momentum readings and pronounced intraday downside pressure.

Sideways consolidation anticipated amid volatility and downside risk

Over the coming sessions, MRNA is likely to range within the volatility band between $175.22 and $200.60. With a 60% probability assigned to downward movement and 40% to a rebound, the baseline scenario expects sideways consolidation unless there is a decisive break from current bounds. Should the price move above resistance at $197.74, a bullish scenario could emerge, while a breach below support may trigger a deeper pullback.

Anton Kharitonov, expert at Traders Union, believes recent FDA approval for Moderna’s mRNA-based flu vaccine expands its market potential, but near-term price sentiment remains cautious. Technically, he sees persistent resistance below key moving averages and a prevailing sell bias from momentum indicators. The stock’s inclusion in the Nasdaq-100 and management updates support longer-term fundamentals, yet short-term technicals dominate. "My base case is sideways action between $175.22 and $200.60, with a risk of deeper pullback if support fails to hold."

Previously it was reported that analysts identified a pivotal moment for Moderna, noting mixed sentiment and heightened volatility despite a bullish long-term trend. The current analysis adds the catalyst of FDA approval for the mRNA flu vaccine but underscores that sustained short-term resistance and seller dominance make a confirmed upside scenario contingent on a break above the $197.74 resistance level.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.